GlaxoSmithKline Depreciation vs Capital Expenditures Analysis

GSK Stock   1,340  3.50  0.26%   
GlaxoSmithKline PLC financial indicator trend analysis is much more than just examining GlaxoSmithKline PLC latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether GlaxoSmithKline PLC is a good investment. Please check the relationship between GlaxoSmithKline PLC Depreciation and its Capital Expenditures accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in GlaxoSmithKline PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

Depreciation vs Capital Expenditures

Depreciation vs Capital Expenditures Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of GlaxoSmithKline PLC Depreciation account and Capital Expenditures. At this time, the significance of the direction appears to have strong relationship.
The correlation between GlaxoSmithKline PLC's Depreciation and Capital Expenditures is 0.68. Overlapping area represents the amount of variation of Depreciation that can explain the historical movement of Capital Expenditures in the same time period over historical financial statements of GlaxoSmithKline PLC, assuming nothing else is changed. The correlation between historical values of GlaxoSmithKline PLC's Depreciation and Capital Expenditures is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Depreciation of GlaxoSmithKline PLC are associated (or correlated) with its Capital Expenditures. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Capital Expenditures has no effect on the direction of Depreciation i.e., GlaxoSmithKline PLC's Depreciation and Capital Expenditures go up and down completely randomly.

Correlation Coefficient

0.68
Relationship DirectionPositive 
Relationship StrengthSignificant

Depreciation

Depreciation indicates how much of GlaxoSmithKline PLC value has been used up. For tax purposes GlaxoSmithKline PLC can deduct the cost of the tangible assets it purchases as business expenses. However, GlaxoSmithKline PLC must depreciate these assets in accordance with IRS rules about how and when the deduction may be taken, and how long it will last. The systematic allocation of the cost of a tangible asset over its useful life.

Capital Expenditures

Capital Expenditures are funds used by GlaxoSmithKline PLC to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of GlaxoSmithKline PLC operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.
Most indicators from GlaxoSmithKline PLC's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into GlaxoSmithKline PLC current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in GlaxoSmithKline PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.
At present, GlaxoSmithKline PLC's Discontinued Operations is projected to increase significantly based on the last few years of reporting.
 2021 2022 2023 2024 (projected)
Interest Expense784M879M775M502.2M
Depreciation And Amortization2.1B2.1B2.3B1.2B

GlaxoSmithKline PLC fundamental ratios Correlations

0.920.210.890.50.890.90.330.610.990.370.590.70.36-0.070.950.95-0.070.680.970.340.910.710.70.120.78
0.920.080.830.410.880.980.410.650.90.350.560.710.42-0.150.910.90.090.710.910.250.870.870.730.030.71
0.210.080.080.780.120.04-0.620.190.160.290.540.370.340.520.040.16-0.38-0.250.060.480.36-0.210.340.670.08
0.890.830.080.30.890.830.530.450.870.490.530.720.420.050.830.940.070.780.940.380.870.720.71-0.070.85
0.50.410.780.30.270.43-0.440.190.490.20.430.370.330.390.290.35-0.6-0.020.310.570.480.250.330.880.46
0.890.880.120.890.270.830.560.740.840.340.660.90.62-0.120.910.970.340.820.940.430.930.710.91-0.20.76
0.90.980.040.830.430.830.380.50.890.370.460.640.36-0.090.870.87-0.010.70.890.270.820.90.650.080.74
0.330.41-0.620.53-0.440.560.380.330.330.010.00.380.32-0.420.440.480.630.750.50.060.30.490.43-0.710.45
0.610.650.190.450.190.740.50.330.560.10.710.710.51-0.370.680.640.460.440.610.090.720.370.77-0.180.31
0.990.90.160.870.490.840.890.330.560.320.50.620.28-0.120.940.92-0.120.650.950.30.850.70.630.130.77
0.370.350.290.490.20.340.370.010.10.320.590.280.240.650.330.39-0.150.340.410.050.520.330.320.040.33
0.590.560.540.530.430.660.460.00.710.50.590.750.630.370.570.640.070.370.580.330.840.320.750.110.38
0.70.710.370.720.370.90.640.380.710.620.280.750.790.060.690.830.360.660.730.620.880.520.98-0.080.64
0.360.420.340.420.330.620.360.320.510.280.240.630.790.280.380.490.330.540.410.750.60.380.8-0.040.53
-0.07-0.150.520.050.39-0.12-0.09-0.42-0.37-0.120.650.370.060.28-0.18-0.05-0.48-0.09-0.090.410.13-0.090.00.420.12
0.950.910.040.830.290.910.870.440.680.940.330.570.690.38-0.180.940.140.760.970.270.870.710.71-0.120.7
0.950.90.160.940.350.970.870.480.640.920.390.640.830.49-0.050.940.150.770.980.410.940.70.82-0.080.78
-0.070.09-0.380.07-0.60.34-0.010.630.46-0.12-0.150.070.360.33-0.480.140.150.40.11-0.070.10.10.43-0.82-0.02
0.680.71-0.250.78-0.020.820.70.750.440.650.340.370.660.54-0.090.760.770.40.80.320.680.770.69-0.380.77
0.970.910.060.940.310.940.890.50.610.950.410.580.730.41-0.090.970.980.110.80.330.910.750.74-0.110.79
0.340.250.480.380.570.430.270.060.090.30.050.330.620.750.410.270.41-0.070.320.330.440.210.540.30.6
0.910.870.360.870.480.930.820.30.720.850.520.840.880.60.130.870.940.10.680.910.440.650.880.060.73
0.710.87-0.210.720.250.710.90.490.370.70.330.320.520.38-0.090.710.70.10.770.750.210.650.55-0.030.76
0.70.730.340.710.330.910.650.430.770.630.320.750.980.80.00.710.820.430.690.740.540.880.55-0.140.63
0.120.030.67-0.070.88-0.20.08-0.71-0.180.130.040.11-0.08-0.040.42-0.12-0.08-0.82-0.38-0.110.30.06-0.03-0.140.14
0.780.710.080.850.460.760.740.450.310.770.330.380.640.530.120.70.78-0.020.770.790.60.730.760.630.14
Click cells to compare fundamentals

GlaxoSmithKline PLC Account Relationship Matchups

GlaxoSmithKline PLC fundamental ratios Accounts

201920202021202220232024 (projected)
Total Assets79.7B80.4B79.1B60.1B59.0B32.8B
Short Long Term Debt Total30.5B27.2B24.2B21.0B18.0B11.0B
Other Current Liab755M13.2B14.7B14.2B13.8B14.5B
Total Current Liabilities24.1B22.1B23.7B22.8B21.1B11.2B
Total Stockholder Equity12.0B14.6B15.1B10.6B13.3B14.0B
Property Plant And Equipment Net11.3B11.0B10.7B9.6B10.0B7.1B
Net Debt25.8B20.9B19.9B17.3B15.1B8.3B
Accounts Payable14.9B4.4B4.5B3.9B3.7B5.0B
Cash4.7B6.3B4.3B3.7B2.9B2.7B
Non Current Assets Total60.2B60.2B60.4B39.4B40.4B20.9B
Non Currrent Assets Other1.2B1.1B1.8B5.3B634M1.0B
Cash And Short Term Investments4.8B6.4B4.3B7.9B5.7B3.9B
Common Stock Shares Outstanding4.0B4.0B3.2B4.1B4.1B4.7B
Liabilities And Stockholders Equity79.7B80.4B79.1B60.1B59.0B32.8B
Non Current Liabilities Total37.3B37.5B34.1B27.2B25.1B14.3B
Inventory5.9B6.0B5.8B5.1B5.5B3.0B
Other Current Assets1.6B1.9B1.7B1.4B1.6B2.8B
Other Stockholder Equity4.9B3.1B3.3B3.7B3.2B2.9B
Total Liab61.3B59.6B57.8B50.1B46.2B25.5B
Property Plant And Equipment Gross11.3B11.0B10.7B9.6B20.2B21.2B
Total Current Assets19.5B20.2B18.7B20.8B18.6B11.9B
Short Term Debt6.9B3.7B3.6B4.0B2.8B2.2B
Common Stock1.3B1.3B1.3B1.3B1.3B1.3B
Retained Earnings5.1B6.8B7.9B4.4B7.2B7.6B
Net Receivables7.1B5.5B6.2B5.5B5.9B5.7B
Accumulated Other Comprehensive Income641M1.6B642M(48M)1.6B1.7B
Intangible Assets31.0B29.8B30.1B14.3B14.8B11.4B
Other Liab13.7B14.1B13.5B10.2B11.7B8.0B
Other Assets5.1B5.3B6.9B6.8B7.8B4.3B
Long Term Debt22.6B22.5B19.8B16.2B14.2B13.5B
Good Will10.6B10.6B10.6B7.0B6.8B4.4B
Property Plant Equipment11.3B11.0B10.7B9.6B11.1B9.7B
Current Deferred Revenue1.4B1.8B1.6B299M222M233.1M
Net Tangible Assets(30.1B)(25.8B)(25.6B)(10.8B)(9.7B)(10.2B)
Short Long Term Debt6.7B3.5B3.4B3.8B2.7B3.9B
Capital Surpluse3.0B3.1B3.2B3.3B3.8B3.4B

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Other Information on Investing in GlaxoSmithKline Stock

Balance Sheet is a snapshot of the financial position of GlaxoSmithKline PLC at a specified time, usually calculated after every quarter, six months, or one year. GlaxoSmithKline PLC Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of GlaxoSmithKline PLC and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which GlaxoSmithKline currently owns. An asset can also be divided into two categories, current and non-current.